Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Early-stage Breast Cancer
Interventions: DRUG: Zoledronate
Sponsor: Ottawa Hospital Research Institute